Quintrio
Home

Stock overview

Oculis Holding AG Ordinary shares

OCS

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

Last trade $7.24
Day change -$0.39 (-5.11%)
Day range $7.08 – $7.76
Volume 103,004
Market cap $425M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for OCS.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for OCS.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Wall Street Analysts Think Oculis Holding AG (OCS) Could Surge 384.89%: Read This Before Placing a Bet

Oculis Holding AG (OCS) has a mean analyst price target of $36.90, suggesting 384.9% upside potential from its current $7.61 price. The stock has a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions over the past 30 days. However, the article cautions that analyst price targets can be misleading and should not be the sole basis for investment decisions, as they often reflect business incentives rather than realistic valuations.

GlobeNewswire Inc.

Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline

Oculis announced an R&D Day on December 8, 2026, to showcase its late-stage pipeline including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. Licaminlimab's PREDICT-1 registrational trial has completed patient randomization with topline results expected around year-end, while Privosegtor is advancing through the PIONEER program with anticipated IND clearance this quarter for acute MS relapse indication.

GlobeNewswire Inc.

Oculis boðar til rannsóknar- og þróunardags (e. R&D Day) bæði í streymi og á staðnum: Framþróun þróunarlyfja með skýra sérstöðu á síðari stigum klínískrar þróunar

Oculis Holding AG announced an R&D Day scheduled for December 8, 2026, to present clinical and strategic milestones for its late-stage development drugs. Licaminlimab, eye drops containing a TNF-α inhibitor for dry eye disease, has completed patient randomization in the PREDICT-1 registrational trial with topline results expected around year-end. Privosegtor, a neuroprotective therapy for optic neuritis and other neuro-axonal diseases, is advancing through the PIONEER program with an anticipated IND application approval this quarter. The company will feature leading international ophthalmology and neurology experts at the virtual and in-person event.

Zacks Investment Research

Oculis Holding AG (OCS) Reports Q3 Loss, Lags Revenue Estimates

Oculis Holding AG (OCS) reported a quarterly loss of $0.37 per share, beating consensus estimates of $0.49 loss by 24.49%, but revenues of $0.01 million significantly missed expectations by 96.93%. The stock has declined 61.4% year-to-date, underperforming the S&P 500's 10.2% gain. Despite the miss, the company maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends.

Zacks Investment Research

Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Oculis Holding AG is expected to report a quarterly loss of $0.49 per share with revenues of $0.29 million for Q3 2026. However, the company has a positive Earnings ESP of +3.09% combined with a Zacks Rank #2 (Buy), suggesting it will likely beat consensus EPS estimates. The company previously delivered a significant earnings surprise of +58.33% in the last quarter.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.